KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Common Equity (2018 - 2025)

Aurinia Pharmaceuticals' Common Equity history spans 8 years, with the latest figure at $581.3 million for Q4 2025.

  • For Q4 2025, Common Equity rose 54.0% year-over-year to $581.3 million; the TTM value through Dec 2025 reached $581.3 million, up 54.0%, while the annual FY2025 figure was $581.3 million, 54.0% up from the prior year.
  • Common Equity reached $581.3 million in Q4 2025 per AUPH's latest filing, up from $365.8 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $581.3 million in Q4 2025 to a low of $298.2 million in Q3 2021.
  • Average Common Equity over 5 years is $392.8 million, with a median of $383.0 million recorded in 2023.
  • Peak YoY movement for Common Equity: dropped 27.17% in 2021, then skyrocketed 54.0% in 2025.
  • A 5-year view of Common Equity shows it stood at $479.1 million in 2021, then decreased by 15.37% to $405.4 million in 2022, then decreased by 6.78% to $378.0 million in 2023, then dropped by 0.13% to $377.5 million in 2024, then surged by 54.0% to $581.3 million in 2025.
  • Per Business Quant, the three most recent readings for AUPH's Common Equity are $581.3 million (Q4 2025), $365.8 million (Q3 2025), and $335.3 million (Q2 2025).